Life Sciences

Why a data and privacy strategy empowers genomics

As we stand on the brink of the personalized medicine era, breakthroughs in areas like genomics are opening up a whole new range of privacy, reliability and security issues. Embedding security and privacy within strategy empowers Life Sciences companies.
1

Genomics – a blueprint for successful outcomes?

This month marks the 16th anniversary of the first full publication of the human genome. Far from being old news, the potential of genomics continues to grow. In what’s already a period of transformation for Life Sciences companies, how can they drive value from genomics, and what are the pitfalls to be avoided?
4 1

Refining relabeling of pharmaceuticals

Patient safety is at the heart of drug development and licensing processes. But the duty of care does not stop at launch. Manufacturers must satisfy strict regulatory demands throughout a product’s lifecycle, including re-labeling.
1

Swiss Life Sciences – ready for R&D 2030?

Digitalization and societal shifts are pushing Life Sciences to the brink of transformation. Over the next decade, successful players will need to redefine their R&D activities in order to rein in expenses, respond to shorter product lifecycles and seize opportunities of personalized medicine.
3

Swap, don’t sell: Driving value through asset swaps

The Swiss Pharmaceuticals sector produced four USD1 billion+ deals in the first half of 2018. This is not surprising given the efforts by Pharmaceuticals and Life Sciences businesses to push new boundaries and continuously innovate.

Expanding right into Europe

Innovation is the life source of Life Sciences. But strategic and meticulous planning is key to commercial success, especially when entering a new regional market.